AGIOS PHARMACEUTICALS, INC.

AGIO · Nasdaq · United States

Share price · AGIO

$29.68-4.72 (-13.72%) 3M

close as of 2026-11-18 · 24h delayed · vol 600K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AGIO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Oct 2026-17.9%

    Nothing announced by AGIO that day or the session before.

  2. 19 Oct 2026+11.4%

    Nothing announced by AGIO that day or the session before.

  3. 30 Jul 2026-6.5%
  4. 21 Jul 2026-6.7%

    Nothing announced by AGIO that day or the session before.

  5. 7 Jul 2026+17.7%

    Nothing announced by AGIO that day or the session before.

  6. 29 Apr 2026+13.1%
  7. 20 Apr 2026-23.0%
  8. 8 Apr 2026-3.8%

    Nothing announced by AGIO that day or the session before.

  9. 31 Mar 2026+14.3%

    Nothing announced by AGIO that day or the session before.

  10. 24 Dec 2025+18.6%

    Nothing announced by AGIO that day or the session before.

Share of unusual movement by asset

For each asset, the share of AGIO's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Mitapivat (Pyrukynd)
events and moves
4shown from 8 days
Mitapivat (Aqvesme) (Aqvesme)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—6%
Other company news (earnings, financing, releases naming no asset)—6%
Sessions with no dated event—88%

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Mitapivat(Pyrukynd)
Approved
Pyruvate kinaseSmall molecule
Sickle Cell DiseasePyruvate Kinase DeficiencyBeta-Thalassemia
Transfusion-Dependent Beta Thalassemia
Approved
Pyruvate kinaseSmall molecule
Beta-Thalassemia
Transfusion-Dependent Beta Thalassemia

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (3)
March 2029 (1)
Mitapivat · PyrukyndPhase 3Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Est. primary completion 2029-03 · NCT07517133 · CT.gov ↗
What to watch
June 2029 (1)
Mitapivat · PyrukyndPhase 3Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
Est. primary completion 2029-06 · NCT07506863 · CT.gov ↗
What to watch
August 2029 (1)
Mitapivat · PyrukyndPhase 3Sickle Cell Disease
Est. primary completion 2029-08 · NCT07656415 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

1 February 2027FDA action dateMitapivatMitapivat sickle cell sNDA PDUFA goal date extended to 1 February 2027
US, FDA · Source ↗

Recent

12 May 2026Filing submittedMitapivatAgios submits mitapivat sNDA for sickle cell disease
US, FDA · AGIOS PHARMACEUTICALS, INC. · Source ↗
November 2025Topline resultMitapivatRISE UP Phase 3 of mitapivat in sickle cell disease (NCT05031780): hemoglobin response met; pain crisis rate not significant
Agios Pharmaceuticals, Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$55M$73M$129M+ $501M short-term inv.$65M-$59M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$45M$101M$100M+ $518M short-term inv.$101M-$57M operating cash flowreport ↗
2026-Q1$21M$81M$114M+ $623M short-term inv.$99M-$119M operating cash flowreport ↗
2025-Q3$13M$87M$93M+ $860M short-term inv.$103M-$88M operating cash flowreport ↗
2025-Q2$12M$92M$81M+ $858M short-term inv.$112M-$77M operating cash flowreport ↗
2025-Q1$8.7M$73M$79M+ $814M short-term inv.$89M-$111M operating cash flowreport ↗
2024-Q3$9.0M$72M$254M+ $751M short-term inv.—-$84M operating cash flowreport ↗
2024-Q2$8.6M$77M$85M+ $485M short-term inv.$96M-$73M operating cash flowreport ↗
2024-Q1$8.2M$69M$119M+ $479M short-term inv.$82M-$100M operating cash flowreport ↗
2023-Q3$7.4M$82M$64M+ $583M short-term inv.$91M-$62M operating cash flowreport ↗
2023-Q2$6.7M$69M$85M+ $618M short-term inv.$84M-$67M operating cash flowreport ↗
2023-Q1$5.6M$67M$104M+ $635M short-term inv.$81M-$95M operating cash flowreport ↗
2022-Q3$3.5M$65M$122M+ $605M short-term inv.$82M-$71M operating cash flowreport ↗
2022-Q2$5.6M$75M$89M+ $731M short-term inv.$92M-$74M operating cash flowreport ↗
2022-Q1$0.8M$70M$80M+ $844M short-term inv.$95M-$98M operating cash flowreport ↗
2021-Q3$0$64M$400M+ $1000M short-term inv.$89M-$85M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$54M$340M$89M+ $765M short-term inv.$103M-$373M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$37M$301M$76M+ $817M short-term inv.—-$390M operating cash flowreport ↗
2023-FY$27M$296M$88M+ $689M short-term inv.$88M-$296M operating cash flowreport ↗
2022-FY$14M$280M$139M+ $644M short-term inv.$58M-$309M operating cash flowreport ↗
2021-FY$0$257M$203M+ $817M short-term inv.—-$407M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 40 sales ($4.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-26Gheuens Sarah · Chief Medical OfficerOption exercise7,866$25.01$197KForm 4
2026-10-26Gheuens Sarah · Chief Medical OfficerOpen-market sale7,866$37.69$296KForm 4
2026-10-26Gheuens Sarah · Chief Medical OfficerOption exercise (derivative)7,866——Form 4
2026-10-22Gheuens Sarah · Chief Medical OfficerOption exercise500$25.01$13KForm 4
2026-10-22Gheuens Sarah · Chief Medical OfficerOpen-market sale500$37.52$19KForm 4
2026-10-22Gheuens Sarah · Chief Medical OfficerOption exercise (derivative)500——Form 4
2026-10-21Gheuens Sarah · Chief Medical OfficerOption exercise1,489$25.01$37KForm 4
2026-10-21Gheuens Sarah · Chief Medical OfficerOpen-market sale1,489$37.53$56KForm 4